Any regulatory or agency response to the ibogaine case reiterates cardiac-safety/QT warnings rather than opening an access pathway, within 90 days.

Ibogaine, a plant-based psychedelic being studied for addiction treatment, carries a serious risk of causing dangerous heart arrhythmias. When any government agency officially responds to a recent ibogaine case or proposal within the next 90 days, they are expected to repeat that heart-risk warning rather than create a new way for people to access it legally. The drug remains in the most restricted category — Schedule I — and one high-profile case won't change that.

Ibogaine's torsadogenic risk is well-documented. Enforcement and safety agencies respond to hype with caution flags, not green lights. One case doesn't move Schedule I posture.